Русский
Multicenter randomized study of bovhyalu-ronidase azoximer (Longidaza®) in men after transuretral resection of the prostate
DOI: https://dx.doi.org/10.18565/urology.2021.3.61-69
S.V. Kotov, A.D. Bolotov, S.V. Belomyttsev, D.N. Surenkov, A.V. Vorobyova
1) Pirogov Russian National Research Medical University, Ministry of Health of Russia, Department of Urology and Andrology, Moscow, Russia; 2) City Clinical Hospital №1 named after N.I. Pirogov, Moscow, Russia; 3) City Clinical Hospital named after V.V. Vinogradov, Moscow, Russia; 4) City Clinical Hospital №29 named after N.E. Bauman, Moscow, Russia
Introduction. Transurethral resection of the prostate (TURP) is the gold standard of BPH surgical treatment. It is of current interest to search for medications that can reduce the incidence of complications after TURP.
Aim. To evaluate the efficiency of Longidaza® (rectal suppositories of 3000 IU) as part of combined therapy in order to prevent complications after TURP.
Materials and methods. The study included 202 patients who underwent TURP in 3 hospitals. The patients were divided into 2 groups: main group – 96 men taking standard postoperative therapy with Longidaza® rectal suppositories N 20; control group – 106 men – taking standard postoperative therapy (tamsulosin 30 days; fluoroquinolone 5 days). Follow-up included IPSS, urinalysis, urine culture, ultrasound examination of the prostate volume (PV), post void residual urine, uroflowmetry at 1,2,3,6 months after surgery. Average preoperative indices: IPSS 27 [23; 30], Qol 5 [4; 6], prostate volume (PV) 71±19cc (30–272 сc), Qmax 7.5±2.5ml/s (1,3–18,7 ml/s).
Results. There was a significant improvement in IPSS, QoL, Qmax, PV, post void residual urine (PVR) compared to preoperative values during the entire observation period. There was no statistical difference between the main and control groups for these indexes in 6 months. In the main group had statistically lower incidence of bacteriuria at 3 (11% vs 17%) and 6 months (7% vs 17%), and leukocyturia at 3 (31% vs 46%) and 6 months of follow-up (20% vs 44%). Overall incidence of infectious complications and additional antibacterial drugs prescription was lower in the Longidaza® group compared to the control group (17,7% vs 20,7%). Urethral strictures developed in 7 men in the main group, and 8 in the control group.
Conclusion. Our results show that prescription of Longidaza® significantly reduces the incidence of leukocyturia and bacteriuria postoperatively, decreasing the rate of infectious complications in men after TURP.
Aim. To evaluate the efficiency of Longidaza® (rectal suppositories of 3000 IU) as part of combined therapy in order to prevent complications after TURP.
Materials and methods. The study included 202 patients who underwent TURP in 3 hospitals. The patients were divided into 2 groups: main group – 96 men taking standard postoperative therapy with Longidaza® rectal suppositories N 20; control group – 106 men – taking standard postoperative therapy (tamsulosin 30 days; fluoroquinolone 5 days). Follow-up included IPSS, urinalysis, urine culture, ultrasound examination of the prostate volume (PV), post void residual urine, uroflowmetry at 1,2,3,6 months after surgery. Average preoperative indices: IPSS 27 [23; 30], Qol 5 [4; 6], prostate volume (PV) 71±19cc (30–272 сc), Qmax 7.5±2.5ml/s (1,3–18,7 ml/s).
Results. There was a significant improvement in IPSS, QoL, Qmax, PV, post void residual urine (PVR) compared to preoperative values during the entire observation period. There was no statistical difference between the main and control groups for these indexes in 6 months. In the main group had statistically lower incidence of bacteriuria at 3 (11% vs 17%) and 6 months (7% vs 17%), and leukocyturia at 3 (31% vs 46%) and 6 months of follow-up (20% vs 44%). Overall incidence of infectious complications and additional antibacterial drugs prescription was lower in the Longidaza® group compared to the control group (17,7% vs 20,7%). Urethral strictures developed in 7 men in the main group, and 8 in the control group.
Conclusion. Our results show that prescription of Longidaza® significantly reduces the incidence of leukocyturia and bacteriuria postoperatively, decreasing the rate of infectious complications in men after TURP.
Keywords: benign prostate hypertrophy, bovhyaluronidase azoximer, transurethral resection of the prostate, Longidaza, complications
About the Autors
Corresponding author: S.V. Kotov – Dr.Med.Sci., head of the department of urology and andrology of Medical faculty Pirogov Russian National Research Medical University, Moscow, Russia; e-mail: urokotov@yandex.ru
Similar Articles
